BiotechTube

Sapropterin

Pre-clinicalCompleted
2 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Phenylketonurias

Conditions

Phenylketonurias

Trial Timeline

Jan 7, 2019 → Sep 10, 2019

NCT ID
NCT03820804

About Sapropterin

Sapropterin is a pre-clinical stage product being developed by BioMarin Pharmaceutical for Phenylketonurias. The current trial status is completed. This product is registered under clinical trial identifier NCT03820804. Target conditions include Phenylketonurias.

What happened to similar drugs?

0 of 3 similar drugs in Phenylketonurias were approved

Approved (0) Terminated (0) Active (3)
🔄sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
🔄sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterinBioMarin PharmaceuticalPhase 3
🔄Sapropterin Dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT03820804Pre-clinicalCompleted
NCT01425528Phase 1/2Completed
NCT01541397Pre-clinicalTerminated
NCT00964236Pre-clinicalCompleted
NCT00935753Phase 2/3Withdrawn

Competing Products

7 competing products in Phenylketonurias

See all competitors
ProductCompanyStageHype Score
PegvaliaseBioMarin PharmaceuticalPre-clinical
23
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 2
32
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
37
sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterinBioMarin PharmaceuticalPhase 3
37
Pegvaliase-PqpzBioMarin PharmaceuticalPre-clinical
23
PalynziqBioMarin PharmaceuticalPre-clinical
30
Sapropterin Dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
37